Mitochondrial ORF of the 12S rRNA type-c. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
The studies behind this compound did not test timing or food state as variables, so we are not going to invent a rule. Pick a time you can keep to consistently.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Option A · once a week a single 5 mg injection each week |
5 mg | once weekly | 0.375 mL | 37.5 u | 1 | 5 mg |
| Option B · daily, 5 on 2 off 1 mg a day for five days, then two days off |
1 mg | 5× weekly | 0.075 mL | 7.5 u | 5 | 5 mg |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial |
|---|---|---|---|---|---|
| Weekly protocol | 5 mg | once weekly | 0.375 mL | 37.5 u | 8 doses |
| Daily protocol | 1 mg | 5× weekly (5 on, 2 off) | 0.075 mL | 7.5 u | 40 doses |
A mitochondrial-derived peptide acting via AMPK on insulin sensitivity and metabolic homeostasis. Genuinely interesting mechanism with solid research data and human observational correlations, but no human dosing trials.
Buy MOTS-cPaid affiliate links.
Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.
Published and reported figures for MOTS-c on these protocols are 5 mg once weekly, or 1 mg a day on a five-days-on two-days-off pattern. This site lists each figure with the source it came from rather than giving a single recommended number.
At 5 mg/mL, a 5 mg dose is 100 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 2 doses.
MOTS-c is graded preclinical. Laboratory and animal data only. No human dosing trials have been published. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.
Need this on one page to print, screenshot or send?
Make a dose card →Side-by-side with the compounds it is most often weighed against — doses, evidence tier and how each is mixed.
Compounds in the same class, or browse the full catalogue.
The principal endogenous intracellular antioxidant tripeptide. Widely administered in clinical settings; the evidence for parenter…
A coenzyme rather than a peptide. Direct NAD+ administration is bioavailability-limited and often poorly tolerated (stinging, flus…
Every compound compared in one table: dose range, how often, half-life and evidence tier.